TY - JOUR
T1 - Association of Galectin-3 with Diabetes Mellitus in the Dallas Heart Study
AU - Vora, Amy
AU - De Lemos, James A.
AU - Ayers, Colby
AU - Grodin, Justin L.
AU - Lingvay, Ildiko
N1 - Funding Information:
Financial Support: This study was supported by a grant from Abbott Diagnostics (to J.A.d.L.) and the Texas Health Resources Clinical Scholars Program (to J.L.G.). C.A. has received consulting fees from National Institutes of Health.
Funding Information:
Disclosure Summary: J.A.d.L. has received grant support from Roche Diagnostics and Abbott Diagnostics and consulting income from Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, Quidel Cardiovascular, and Novo Nordisk. I.L. has received research funding and/or consulting/other fees from NovoNordisk, Lilly, Sanofi, AstraZeneca, Boehringer-Ingelheim, Valeritas, MannKind, Intarcia, TARGETPharma, Novartis, Merck, and Mylan. C.A. has received consulting fees from National Institutes of Health. The remaining authors have nothing to disclose.
Publisher Copyright:
Copyright © 2019 Endocrine Society.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Context: Galectin-3 is a biomarker associated with inflammation and fibrosis in cardiac, liver, and renal disease. Galectin-3 is higher in overweight and obese individuals; whether an association with diabetes exists independent of weight is unknown. Objective: To evaluate if galectin-3 is associated with diabetes mellitus. Design: We performed measurements of galectin-3 among participants in the Dallas Heart Study (DHS) Phases 1 and 2 (DHS-1 and DHS-2; n = 3392, and n = 3194, respectively). Of these, 1989 participants were evaluated longitudinally in both studies. Associations of galectin-3 with prevalent and incident type 2 diabetes were determined using logistic regression models. Associations of galectin-3 with relevant biomarkers and fat compartments were evaluated using Spearman correlation coefficients and multivariable linear regression models, respectively. Setting and Participants: DHS is a population-based, single-site, multiethnic study conducted in Dallas County, Texas, with oversampling to comprise 50% blacks. Results: Galectin-3 levels were associated with diabetes prevalence in DHS-1 [OR 1.56 per SD change in log-galectin (95% CI 1.41 to 1.73)] and DHS-2 [OR 1.86 (95% CI 1.67 to 2.06)]. Galectin-3 levels in DHS-1 also associated with incident diabetes mellitus over the 7.1 (interquartile range 6.6 to 7.6)-year follow-up period [OR 1.34 (95% CI 1.14 to 1.58)]. These associations maintained significance in models adjusted for traditional metabolic risk factors (age, sex, race, body mass index, and hypertension) and renal function. Galectin-3 levels correlated with levels of biomarkers implicated in inflammation (high-sensitivity C-reactive peptide, IL-18, monocyte chemoattractant protein 1, soluble TNF receptor 1A, myeloperoxidase), insulin secretion (C-peptide and C-peptide/homeostatic model assessment for insulin resistance), and subcutaneous adiposity. Conclusions: Galectin-3 is associated with diabetes prevalence and incidence, possibly through the inflammatory pathway contributing to β-cell fibrosis and impaired insulin secretion.
AB - Context: Galectin-3 is a biomarker associated with inflammation and fibrosis in cardiac, liver, and renal disease. Galectin-3 is higher in overweight and obese individuals; whether an association with diabetes exists independent of weight is unknown. Objective: To evaluate if galectin-3 is associated with diabetes mellitus. Design: We performed measurements of galectin-3 among participants in the Dallas Heart Study (DHS) Phases 1 and 2 (DHS-1 and DHS-2; n = 3392, and n = 3194, respectively). Of these, 1989 participants were evaluated longitudinally in both studies. Associations of galectin-3 with prevalent and incident type 2 diabetes were determined using logistic regression models. Associations of galectin-3 with relevant biomarkers and fat compartments were evaluated using Spearman correlation coefficients and multivariable linear regression models, respectively. Setting and Participants: DHS is a population-based, single-site, multiethnic study conducted in Dallas County, Texas, with oversampling to comprise 50% blacks. Results: Galectin-3 levels were associated with diabetes prevalence in DHS-1 [OR 1.56 per SD change in log-galectin (95% CI 1.41 to 1.73)] and DHS-2 [OR 1.86 (95% CI 1.67 to 2.06)]. Galectin-3 levels in DHS-1 also associated with incident diabetes mellitus over the 7.1 (interquartile range 6.6 to 7.6)-year follow-up period [OR 1.34 (95% CI 1.14 to 1.58)]. These associations maintained significance in models adjusted for traditional metabolic risk factors (age, sex, race, body mass index, and hypertension) and renal function. Galectin-3 levels correlated with levels of biomarkers implicated in inflammation (high-sensitivity C-reactive peptide, IL-18, monocyte chemoattractant protein 1, soluble TNF receptor 1A, myeloperoxidase), insulin secretion (C-peptide and C-peptide/homeostatic model assessment for insulin resistance), and subcutaneous adiposity. Conclusions: Galectin-3 is associated with diabetes prevalence and incidence, possibly through the inflammatory pathway contributing to β-cell fibrosis and impaired insulin secretion.
UR - http://www.scopus.com/inward/record.url?scp=85071997166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071997166&partnerID=8YFLogxK
U2 - 10.1210/jc.2019-00398
DO - 10.1210/jc.2019-00398
M3 - Article
C2 - 31162551
AN - SCOPUS:85071997166
VL - 104
SP - 4449
EP - 4458
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 10
ER -